FindTrial
Sign In

Development and validation of AI model to predict the surgical site infection in lung cancer surgery

Development and validation of AI model to predict the surgical site infection in lung cancer surgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043271
Enrollment
Unknown
Registered
2021-02-09
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Gold Standard:Clinical outcome
Index test:The&#32
artificial&#32
intelligence-based&#32
model&#32
to&#32
predict&#32
the&#32
outcome&#32
of&#32
surgical&#32
site&#32
infection&#32
(SSI)&#32
after&#32
minimally&#32
invasive&#32
lung&#32
cancer&#32
surgery.

Sponsors

Shanghai Chest Hospital/ Shanghai Jiao Tong University Affiliated Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Adult patients who meet the diagnosis of lung cancer and have undergone minimally invasive surgery.

Exclusion criteria

Exclusion criteria: 1. Patients with immunodeficiency syndrome; 2. Long-term use of immunosuppressive agents; 3. Emergency or trauma patients; 4. data is missing or incomplete.

Design outcomes

Primary

MeasureTime frame
surgical site infection, SSI;SEN, SPE, ACC, AUC of ROC;Postoperative hospital stay;28-day emergency hospitalization;—

Countries

China

Contacts

Public ContactHou Xumin

Shanghai Chest Hospital/ Shanghai Jiao Tong University Affiliated Chest Hospital

hxmchest@163.com+86 18017320200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026